Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.

Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM.

J Clin Pharmacol. 2009 Mar;49(3):351-9. doi: 10.1177/0091270008331196.

PMID:
19246732
2.

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.

Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA, Hall SD.

Drug Metab Dispos. 2006 Jul;34(7):1208-19. Epub 2006 Apr 12.

3.

The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.

Oo C, Chen YC.

J Clin Pharmacol. 2009 Mar;49(3):368-9; author reply 370. doi: 10.1177/0091270008325931. No abstract available.

PMID:
19246734
4.
5.

Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.

Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, Fitzgerald M, Chodakewitz J, Wagner JA.

J Clin Pharmacol. 2009 Apr;49(4):398-406. doi: 10.1177/0091270008331133. Epub 2009 Feb 26.

PMID:
19246722
6.

Drug-drug interactions between ketoconazole and berberine in rats: pharmacokinetic effects benefit pharmacodynamic synergism.

Zhou Y, He P, Liu A, Zhang L, Liu Y, Dai R.

Phytother Res. 2012 May;26(5):772-7. doi: 10.1002/ptr.3621. Epub 2011 Nov 24.

PMID:
22114028
7.

Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.

Tham LS, Lee HS, Wang L, Yong WP, Fan L, Ong AB, Sukri N, Soo R, Lee SC, Goh BC.

Ther Drug Monit. 2006 Apr;28(2):255-61.

PMID:
16628140
8.
9.

Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.

Kaeser B, Zandt H, Bour F, Zwanziger E, Schmitt C, Zhang X.

Antimicrob Agents Chemother. 2009 Feb;53(2):609-14. doi: 10.1128/AAC.00769-08. Epub 2008 Nov 17.

10.

Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.

Ogasawara A, Kume T, Kazama E.

Drug Metab Dispos. 2007 Mar;35(3):410-8. Epub 2006 Dec 1.

11.
12.
13.
14.

Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs.

Kuroha M, Kayaba H, Kishimoto S, Khalil WF, Shimoda M, Kokue E.

J Pharm Sci. 2002 Mar;91(3):868-73.

PMID:
11920771
15.

Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers.

Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sunbhanich M.

J Clin Pharm Ther. 2005 Jun;30(3):285-90.

PMID:
15896247
16.

Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs.

Kuroha M, Azumano A, Kuze Y, Shimoda M, Kokue E.

Drug Metab Dispos. 2002 Jan;30(1):63-8.

17.

The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.

Kovarik JM, Huang HL, Slade A, Sfikas N, Chandler PA.

Br J Clin Pharmacol. 2009 Sep;68(3):381-5. doi: 10.1111/j.1365-2125.2009.03457.x.

18.

Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates.

Dilmaghanian S, Gerber JG, Filler SG, Sanchez A, Gal J.

Chirality. 2004 Feb;16(2):79-85.

PMID:
14712470
19.
20.

Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.

Han B, Mao J, Chien JY, Hall SD.

Drug Metab Dispos. 2013 Jul;41(7):1329-38. doi: 10.1124/dmd.112.050732. Epub 2013 Apr 12.

Supplemental Content

Support Center